Databricks' KARL agent uses reinforcement learning to generalize across six enterprise search behaviors — the problem that breaks most RAG pipelines.
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results